We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Modified Botulinum Toxin Targets Nerve Cells and Reverses Paralysis in Mice
News

Modified Botulinum Toxin Targets Nerve Cells and Reverses Paralysis in Mice

Modified Botulinum Toxin Targets Nerve Cells and Reverses Paralysis in Mice
News

Modified Botulinum Toxin Targets Nerve Cells and Reverses Paralysis in Mice

The toxin-based delivery platform consists of the modified botulinum toxin at upper left (protease domain in gold, translocation domain in blue, and receptor-binding domain in purple) and the nanobody (the pink tag). When this nanobody-toxin fusion protein binds to the receptor (cyan) on the neuron surface, the cell takes it in through the process of endocytosis, corralling the fusion protein inside a vesicle (light green circle). The toxin's protease domain, carrying the nanobody, then crosses into the interior of the cell. Credit: Sicai Zhang/Dong Lab, Boston Children's Hospital
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Modified Botulinum Toxin Targets Nerve Cells and Reverses Paralysis in Mice"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

While rare, botulism can cause paralysis and is potentially fatal. It is caused by nerve-damaging toxins produced by Clostridium botulinum — the most potent toxins known. These toxins often lurk in contaminated food (home canning being a major culprit). Infants can also develop botulism from ingesting C. botulinum spores in honey, soil, or dust; the bacterium then colonizes their intestines and produces the toxin.

Key takeaway


A modified botulinum toxin efficiently targets and enters nerve cells, delivering a miniature antibody that reversed paralysis in mice.

Once paralysis develops, there is no way to reverse it, other than waiting for the toxins to wear off. People with serious cases may need to go on ventilators for weeks or months. But a new botulism treatment and delivery vehicle, described today in Science Translational Medicine, could change that.

“Currently, there are anti-toxins, but these only work before the toxins enter the motor neurons,” says Min Dong, PhD, a researcher in the Boston Children’s Hospital Department of Urology and corresponding author on the paper. “What we have developed is the first therapy that can eliminate toxins after they get inside neurons.”

If proven in humans, the approach would represent a breakthrough in treating botulism. In mice, the treatment successfully got inside neurons and reversed muscle paralysis within hours. It also enabled mice to withstand doses of botulinum toxin that would otherwise be lethal.

A botulism treatment, steered by a toxin


Dong and his colleagues needed to surmount two technical barriers that have so far thwarted effective botulism treatment. Intriguingly, their solution lay in botulinum toxin itself.

“One barrier to treatment has been getting across the cell membrane, which is difficult for protein drugs,” explains first author Shin-Ichiro Miyashita, PhD, a postdoctoral fellow in Dong’s lab. “The other is targeting specific cell types, and in this case specificity toward motor neurons and nerve terminals. We took advantage of the fact that botulinum neurotoxins naturally target motor neurons and can deliver a protein cargo across cell membranes.”

The treatment harnesses a botulinum toxin (detoxified through introduced mutations) as the delivery vehicle. The cargo — the active drug — is a mini-antibody derived from the antibodies of camels, developed by collaborator Charles Shoemaker, PhD, at Tufts University.  Two of these so-called nanobodies can be delivered in tandem into neurons, neutralizing botulinum toxins type A and B at one go, the team showed.

Taming the toxin


But there was one more problem to solve.

“This approach had been attempted, but it was difficult to completely get rid of toxicity,” says Dong, “until we identified botulinum neurotoxin X in 2017. Unlike other botulinum toxins, this new toxin shows no toxicity after we introduce mutations, and serves as a safe delivery tool.”

Botox reversal


Besides botulism, Dong thinks the new treatment could be useful as a “botox reversal” agent. Botox injections, using tiny quantities of the type A botulinum toxin, can safely treat wrinkles and many other medical conditions like neck spasms, excessive sweating, or overactive bladder. However, when the injection goes awry, botox can cause unwanted muscle paralysis as a side effect, and patients have to live with the paralysis for months.

“We can potentially inject our therapeutic protein and get rid of botox in neurons and paralysis within a few hours,” Dong says.

A general delivery platform for neuroactive drugs?


The toxin-guided approach may offer a platform for getting biologic drugs into neurons to treat other disorders, Dong believes. Currently, most biologic drugs act only on cell-surface targets and cannot get into the cell’s interior.

“We provide a protein-based drug delivery platform that achieves highly specific targeting of neurons and efficient penetration of cell membranes,” Dong says. “Combined with nanobodies, which can be developed fairly readily against any protein of interest, this platform can be used to develop therapeutics that modulate proteins and biological processes inside neurons. Its modular nature even allows us to target cell types other than neurons by switching the cell-targeting domain. This could present a general approach for precision drug delivery into cells.”

Reference: Miyashita S-I, Zhang J, Zhang S, Shoemaker CB, Dong M. Delivery of single-domain antibodies into neurons using a chimeric toxin–based platform is therapeutic in mouse models of botulism. Sci. Transl. Med. 2021;13(575). doi:10.1126/scitranslmed.aaz4197

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement